Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial
Identifieur interne : 001854 ( Istex/Checkpoint ); précédent : 001853; suivant : 001855Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial
Auteurs : Dan A. Mendonça [Canada] ; Krishe Menezes [Canada] ; Mandar S. Jog [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-10-31.
English descriptors
Abstract
Fatigue is a common nonmotor symptom in idiopathic Parkinson disease (IPD) that can prominently affect everyday function. This study was a randomized, double‐blind, placebo‐controlled trial evaluating methylphenidate for the treatment of fatigue in patients with IPD maintained on their regular medications. Thirty‐six patients were randomized to receive either methylphenidate (10 mg three times per day; n = 17) or placebo (n = 19) for 6 weeks. Primary outcomes were the change from baseline on two separate self‐report fatigue questionnaires: the Fatigue Severity Scale (FSS) and the Multidimensional Fatigue Inventory (MFI). Secondary outcomes included the Unified Parkinson Disease Rating Scale (UPDRS) motor score and the five individual domains of the MFI. Fourteen patients in the methylphenidate group and 16 patients in the control group remained on the intervention for the entire study period. In the treatment arm, mean FSS score was reduced by 6.5 points (from a baseline of 43.8) and mean MFI score was reduced by 8.4 points (from a baseline of 51.0). Both these reductions were significant (P < 0.04). Smaller reductions in the placebo group were nonsignificant. Mean UPDRS motor score did not change significantly in either group. Analysis of MFI subscores showed a significant reduction in General Fatigue in the methylphenidate group (P < 0.001). Overall, adverse effects of medication were more frequent in the placebo group. In conclusion, methylphenidate was effective in lowering fatigue scores in patients with IPD following a 6‐week treatment period. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21656
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:C1D32DDE18D7567B439433CCEB6360B4E7088BF9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial</title>
<author><name sortKey="Mendonca, Dan A" sort="Mendonca, Dan A" uniqKey="Mendonca D" first="Dan A." last="Mendonça">Dan A. Mendonça</name>
</author>
<author><name sortKey="Menezes, Krishe" sort="Menezes, Krishe" uniqKey="Menezes K" first="Krishe" last="Menezes">Krishe Menezes</name>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:C1D32DDE18D7567B439433CCEB6360B4E7088BF9</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21656</idno>
<idno type="url">https://api.istex.fr/document/C1D32DDE18D7567B439433CCEB6360B4E7088BF9/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001046</idno>
<idno type="wicri:Area/Istex/Curation">001046</idno>
<idno type="wicri:Area/Istex/Checkpoint">001854</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial</title>
<author><name sortKey="Mendonca, Dan A" sort="Mendonca, Dan A" uniqKey="Mendonca D" first="Dan A." last="Mendonça">Dan A. Mendonça</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Menezes, Krishe" sort="Menezes, Krishe" uniqKey="Menezes K" first="Krishe" last="Menezes">Krishe Menezes</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Clinical Neurosciences, University of Western Ontario, London, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-10-31">2007-10-31</date>
<biblScope unit="vol">22</biblScope>
<biblScope unit="issue">14</biblScope>
<biblScope unit="page" from="2070">2070</biblScope>
<biblScope unit="page" to="2076">2076</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">C1D32DDE18D7567B439433CCEB6360B4E7088BF9</idno>
<idno type="DOI">10.1002/mds.21656</idno>
<idno type="ArticleID">MDS21656</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson disease</term>
<term>fatigue</term>
<term>methylphenidate</term>
<term>randomized controlled trial</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Fatigue is a common nonmotor symptom in idiopathic Parkinson disease (IPD) that can prominently affect everyday function. This study was a randomized, double‐blind, placebo‐controlled trial evaluating methylphenidate for the treatment of fatigue in patients with IPD maintained on their regular medications. Thirty‐six patients were randomized to receive either methylphenidate (10 mg three times per day; n = 17) or placebo (n = 19) for 6 weeks. Primary outcomes were the change from baseline on two separate self‐report fatigue questionnaires: the Fatigue Severity Scale (FSS) and the Multidimensional Fatigue Inventory (MFI). Secondary outcomes included the Unified Parkinson Disease Rating Scale (UPDRS) motor score and the five individual domains of the MFI. Fourteen patients in the methylphenidate group and 16 patients in the control group remained on the intervention for the entire study period. In the treatment arm, mean FSS score was reduced by 6.5 points (from a baseline of 43.8) and mean MFI score was reduced by 8.4 points (from a baseline of 51.0). Both these reductions were significant (P < 0.04). Smaller reductions in the placebo group were nonsignificant. Mean UPDRS motor score did not change significantly in either group. Analysis of MFI subscores showed a significant reduction in General Fatigue in the methylphenidate group (P < 0.001). Overall, adverse effects of medication were more frequent in the placebo group. In conclusion, methylphenidate was effective in lowering fatigue scores in patients with IPD following a 6‐week treatment period. © 2007 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Mendonca, Dan A" sort="Mendonca, Dan A" uniqKey="Mendonca D" first="Dan A." last="Mendonça">Dan A. Mendonça</name>
</noRegion>
<name sortKey="Jog, Mandar S" sort="Jog, Mandar S" uniqKey="Jog M" first="Mandar S." last="Jog">Mandar S. Jog</name>
<name sortKey="Menezes, Krishe" sort="Menezes, Krishe" uniqKey="Menezes K" first="Krishe" last="Menezes">Krishe Menezes</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001854 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 001854 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Checkpoint |type= RBID |clé= ISTEX:C1D32DDE18D7567B439433CCEB6360B4E7088BF9 |texte= Methylphenidate improves fatigue scores in Parkinson disease: A randomized controlled trial }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |